NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

On the other hand it might not make sense to call it starting over again. The now have a very large pool of patients. Waiting for more events is not nearly as difficult or expensive as starting patients in the trial. If they were previously dealing with a huge percentage event rate, then they would be saturated for that early group. It would be very difficult for them to gather so many more, but they were not at a huge percentage event rate. Though the giant tail becomes less useful.

Not to say the numbers listed are not a serious squeeze for events.